[PDF][PDF] Re-programing chromatin with a bifunctional LSD1/HDAC inhibitor induces therapeutic differentiation in DIPG

JN Anastas, BM Zee, JH Kalin, M Kim, R Guo… - Cancer cell, 2019 - cell.com
JN Anastas, BM Zee, JH Kalin, M Kim, R Guo, S Alexandrescu, MA Blanco, S Giera…
Cancer cell, 2019cell.com
Summary H3K27M mutations resulting in epigenetic dysfunction are frequently observed in
diffuse intrinsic pontine glioma (DIPGs), an incurable pediatric cancer. We conduct a
CRISPR screen revealing that knockout of KDM1A encoding lysine-specific demethylase 1
(LSD1) sensitizes DIPG cells to histone deacetylase (HDAC) inhibitors. Consistently, Corin,
a bifunctional inhibitor of HDACs and LSD1, potently inhibits DIPG growth in vitro and in
xenografts. Mechanistically, Corin increases H3K27me3 levels suppressed by H3K27M …
Summary
H3K27M mutations resulting in epigenetic dysfunction are frequently observed in diffuse intrinsic pontine glioma (DIPGs), an incurable pediatric cancer. We conduct a CRISPR screen revealing that knockout of KDM1A encoding lysine-specific demethylase 1 (LSD1) sensitizes DIPG cells to histone deacetylase (HDAC) inhibitors. Consistently, Corin, a bifunctional inhibitor of HDACs and LSD1, potently inhibits DIPG growth in vitro and in xenografts. Mechanistically, Corin increases H3K27me3 levels suppressed by H3K27M histones, and simultaneously increases HDAC-targeted H3K27ac and LSD1-targeted H3K4me1 at differentiation-associated genes. Corin treatment induces cell death, cell-cycle arrest, and a cellular differentiation phenotype and drives transcriptional changes correlating with increased survival time in DIPG patients. These data suggest a strategy for treating DIPG by simultaneously inhibiting LSD1 and HDACs.
cell.com